Here is the design of a clinical trial:

Official Title: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial

Included conditions:
- Coronary Artery Disease
- Myocardial Ischemia
- Acute Coronary Syndrome
- Heart Diseases
- Syndrome Heart Disease
- Cardiovascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Vascular Diseases

Study Armgroups:
- {'label': 'Aspirin monotherapy', 'type': 'PLACEBO_COMPARATOR', 'description': 'Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.', 'interventionNames': ['Drug: Aspirin monotherapy']}
- {'label': 'Clopidogrel and Aspirin dual-antiplatelet therapy', 'type': 'EXPERIMENTAL', 'description': 'Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.', 'interventionNames': ['Drug: Clopidogrel and Aspirin dual-antiplatelet therapy']}

Interventions:
- {'type': 'DRUG', 'name': 'Clopidogrel and Aspirin dual-antiplatelet therapy', 'description': 'Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.', 'armGroupLabels': ['Clopidogrel and Aspirin dual-antiplatelet therapy']}
- {'type': 'DRUG', 'name': 'Aspirin monotherapy', 'description': 'Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.', 'armGroupLabels': ['Aspirin monotherapy']}

Primary Outcomes:
- {'measure': 'Incidence of MACCE(cardiovascular death, nonfatal myocardial infarction or nonfatal stroke).', 'description': 'To evaluate the effect of Clopidogrel and Aspirin dual-antiplatelet therapy on the incidence of MACCE in patients with MVD', 'timeFrame': 'Through study completion, an average of 2 years.'}

Please estimate the sample size based on the assumption: 
A two-sided test at the 5% significance level, 80% power, 5% dropout rate, and 3% noncompliance rate. The enrollment duration is 24 months with a follow-up time of at least 12 months (median follow-up time of 24 months). Randomization is 1:1.
2.6
        Sample Size Calculation
        Based on data extracted from the PEGASUSâTIMI 54 study, the expected annual rate of MACCEs is estimated to be 5% in the control arm [19]. It is anticipated that prolonged DAPT treatment in patients with MVD will reduce the target relative risk by 20% (i.e., the hazard ratio [treatment/control] is equal to 0.8) and the perâyear event rate by approximately 4% for the primary endpoint in those populations [20, 21]. Moreover, a twoâsided test is set at the 5% significance level, and 80% power is designed to reject the null hypothesis. The enrollment duration is estimated to be 24 months, and the followâup time is at least 12 months (with an expected median followâup time of 24 months). The enrollment progress in both groups was consistent, and eligible patients will be randomized on a 1:1 basis according to the protocol. Considering a 5% dropout rate and an expected noncompliance (switching groups) rate in those groups will be 3%. Therefore, the DAPTâMVD trial is required to enroll at least 8250 subjects (4125 in each arm).